Program
Palivizumab
Also written as “Palivizumab 15 mg/kg”, “Lyophilized Palivizumab” and “Liquid Palivizumab”.
Its studies are mostly in Respiratory Syncytial Virus Infections · Bronchopulmonary Dysplasia · Bronchiolitis, led by 5 companies.
Drug pagePalivizumab: every studyMany companies study it; this page follows only the 9 they lead. All 10 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 41 open or running | phase 4since Oct 3, 2005 | Oct 3, 2005 | Feb 28, 2027NCT06851806 |
| AbbVieits history only | 20 open or running | phase 3since Sep 12, 2011 | Sep 12, 2011 | none ahead |
| Abbott | 10 open or running | phase 3since Nov 2, 2009 | Nov 2, 2009 | none ahead |
| Fresenius Kabiits history only | 10 open or running | phase 1since Jul 24, 2020 | Jul 24, 2020 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since May 10, 2015 | May 10, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2009First study: phase 3 study in Respiratory Syncytial Virus InfectionsFirst studyNCT01006629 · 100 enrolled · Russian Federation
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule
Studies
The one study Abbott leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01006629Respiratory Syncytial Virus Infections · Russian Federation | 3 | Completed | Apr 2010 | 100 |
How it is read
Names in the registry
- “Palivizumab”, 4 entries
- “Palivizumab 15 mg/kg”, 1 entry
- “Lyophilized Palivizumab”, 1 entry
- “Liquid Palivizumab”, 1 entry
- “Motavizumab, palivizumab”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 3 studies
- Bronchopulmonary Dysplasia, 1 study
- Bronchiolitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.